



HTA Assessment in Germany, Spain, the UK and the EU

Your speakers

National HTA systems,
pricing and
harmonisation efforts
from Joint Action 3



Dr Alexander Natz, LL.M
– Chair –
EUCOPE – European Confederation
of Pharmaceutical Entrepreneurs,
Brussels, BELGIUM
Secretary General



Dr Hannah Brühl
Federal Joint Committee (G-BA),
Berlin, GERMANY
Scientific Advisor, Pharmaceuticals
Department



Dirk Eheberg
QuintilesIMS, Munich, GERMANY
Director Health Economics &
Outcomes Research



Sabine Ettinger, MSc
Ludwig Boltzmann Institute for
Health Technology Assessment,
Vienna, AUSTRIA
EUnetHTA JA3 WP4 Co-Lead
Project Management



Andrew Gapper
MAP BioPharma,
Cambridge, GREAT BRITAIN
Associate Director
Service Development



Dr Antoni Gilabert
Catalan Health and Social Care
Consortium (CSC), Barcelona, SPAIN
Director of Pharmacy and Medicines



Christian Hill
MAP BioPharma, Cambridge,
GREAT BRITAIN
Director Market Access &
Government Affairs



Dr François Meyer
French National Authority for
Health (HAS), FRANCE
Advisor to the HAS President –
International Affairs



Thomas Müller
Federal Joint Committee (G-BA),
Berlin, GERMANY
Head of Pharmaceuticals Department

Thursday, 28 September 2017

09:00

Value assessment of pharmaceuticals in Europe – status quo 2017

Dr François Meyer

- Joint Action 3 at a glance
- Results of public consultation
- Rapid REA – 2017 insights
- Participation of EUnetHTA in EMA's initiatives

09:45

WP5 of EUnetHTA Joint Action 3: Evidence generation

Hannah Brühl, Dr François Meyer

- The current status of early dialogues
 - Cooperation of the national HTA agencies
 - Harmonised early advice in Europe?
- Post-launch evidence
 - Registers and the register data in HTAs
 - Generating Real-World Evidence after the HTA – acceptance by the authorities

11:00 Coffee break

11:15

National peculiarities and political implications

Thomas Müller

- From early dialogues to early assessment
- The German position on HTA harmonisation in the EU – early dialogues in Europe
- Current changes after the latest AMNOG reform

12:00

Generating Real-World Evidence in practice

Dirk Eheberg

- Electronic patient health records
- Data from patient organisations
- Patient-reported and patient-centred outcomes
- How to use the possibilities

13:00 Lunch

14:30

Jointly produced European HTAs in (non-pharma) medical interventions – A possibility to avoid redundancy?

Sabine Ettinger

- Jointly produced HTAs – tools
- Production process
- Stakeholder involvement
- Decentralisation and division of labour (activity centres)
- Experiences

15:30

Discussion round:

What comes after Joint Action 3?

Dr Hannah Brühl, Sabine Ettinger, Dr François Meyer, Thomas Müller, Dr Alexander Natz

16:00 Coffee break

16:15

Early access possibilities and challenges in Europe

Christian Hill

- Precondition: unmet medical need?
- Named-patient programmes
- National differences such as the French ATU and the UK EAMS
- Implications of early access schemes for HTA and pricing at a later stage

17:30 End of day one

Friday, 29 September 2017

09:00

Medicines evaluation in Spain: from regulatory/HTA to market access – the experience in Catalonia

Antoni Gilabert

- Who's who in medicines evaluation in Spain
- How does HTA influence market access for medicines?
- The Catalan model for equity access to drugs and the role of HTAs

10:00

HTA in the UK and Ireland: NICE, SMC, AWMSG, NCPE

Andrew Gapper

- Horizon scanning in the UK
- HTA trends in the UK and Ireland
- Evolution of NICE technology appraisal, HST and further programmes
- Specialised conditions – what happens when NICE HTA does not apply?
- Predicting the implications of BREXIT

11:00 Coffee break

11:15

Price confidentiality and transparency in Europe

Dr Alexander Natz

12:15 Lunch

13:30

Case study: From HTA to pricing

Christian Hill

- Launch sequencing and pricing strategy in Europe

15:00 End of conference

Aims and objectives

HTA/value assessment is an essential tool in many national European healthcare systems.

This conference provides thorough insights into the national procedures in Germany, Spain, the UK and Ireland. It also provides a sound update on European harmonisation efforts in terms of harmonised early advice or joint HTAs.

Early access availability, pricing and pricing strategies will round off the conference, enabling you to optimise your market access strategy for the various European markets.

Who should attend?

This conference addresses the needs of employees in the pharmaceutical industry responsible for market access activities in the various national European markets.

Those involved in value-assessment preparation and pricing activities will benefit particularly from this conference.

Your benefits

- Experts from various national HTA bodies discuss the current challenges and perspectives
- Focus on European harmonisation efforts and national peculiarities
- First-hand information on Joint Action 3 proceedings

Quality guaranteed

IMI (Innovative Medicines Initiative) defined quality criteria for professional training and education. We follow these criteria and, as a signatory, we are an active partner in further developing and optimising the quality standards.

An aggregate evaluation of participants' feedback on all FORUM's healthcare training courses (evaluation period from 10.2015 - 09.2016) produced a result of 1.7 (based on a school grading system of 1-6).

Registration under
formacion@qualitecfarma.com or
Telf.: +34 91 372 83 99

Registration Form

Yes, I will attend the conference

HTA Assessment in Germany, Spain, the UK and the EU

Name

Position/Department

Company

Street

Postal Code/City/Country

Tel. No.

E-Mail

Contact person at office

Date, Signature

How to Register

Registration: +34 91 372 83 99

Conference No. 17 09 232

Internet:

www.qualitecfarma.com

Date / Venue:

28 - 29 September 2017 in Berlin

1st day: 08:30 registration, 09:00 -17:30 conference

2nd day: 09:00 -15:00 conference

Mercure Hotel MOA Berlin

Stephanstr. 41 · 10559 Berlin

Tel.: +49 30 394043-0 · Fax: +49 30 394043-999

Fee:

€ 1,890.00 (+ German VAT)

The fee includes course documentation (incl. free download) as well as midsession refreshments, lunch and certificate.

Hotel accommodations:

A limited number of rooms have been reserved at the hotel and are subject to availability. Please book at least six weeks prior to the seminar to obtain a hotel room at the discounted rate. All bookings should be made directly with the hotel quoting FORUM Institut and the Course No.

Any Further Questions?

Please feel free to contact me if you have any questions.

Pablo García

Conference Manager

Tel. +34 91 372 83 99

formacion@qualitecfarma.com

Cancellation Policy

Our general terms and conditions apply (as of 1 January 2016) and are available upon request. We can send them to you anytime or you can find them on the internet at www.forum-institut.com/t&c